Celadon Pharmaceuticals (CEL) Share Price, News & Analysis

Company Overview

Celadon Pharmaceuticals Plc engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines. The company primarily focuses on growing indoor hydroponic cannabis for use in medicinal products used to treat chronic pain, as well as autism spectrum disorders. Celadon Pharmaceuticals Plc was founded in 2018 and is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: 25.38 to 30
• 50-Day Range: 24 to 54
• 52-Week Range: 20 to 130
• Volume: 26,527 shs
• Average Volume: 77,233 shs
• Market Capitalization: £18.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CEL Stock Analysis - Frequently Asked Questions

How have CEL shares performed this year?

Celadon Pharmaceuticals' stock was trading at GBX 115 on January 1st, 2024. Since then, CEL stock has decreased by 76.1% and is now trading at GBX 27.50.
View the best growth stocks for 2024 here.

How do I buy shares of Celadon Pharmaceuticals?

Shares of CEL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Celadon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Celadon Pharmaceuticals investors own include AutoZone (AZO), Bahamas Petroleum (BPC), Intel (INTC), TJX Companies (TJX), Abacus Health Products (ABAHF), Avino Silver & Gold Mines (ASM) and Avino Silver & Gold Mines (ASM).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Communication
• Current Symbol: LON:CEL
• CUSIP: N/A
• CIK: N/A
• Web: www.celadonpharma.co.uk
• Phone: 44 20 3150 0252
• Fax: N/A
• Employees: 2,780
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-5,230,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -190.71%
• Return on Assets: -34.40%

Debt

• Debt-to-Equity Ratio: 194.82
• Current Ratio: 1.92
• Quick Ratio: 6.97

Sales & Book Value

• Annual Sales: £11,258.00
• Price / Sales: 1,681.80
• Cash Flow: GBX 9.01 per share
• Price / Cash Flow: 3.05
• Book Value: GBX 4 per share
• Price / Book: 6.88

Miscellaneous

• Outstanding Shares: 68,850,000
• Free Float: N/A
• Market Cap: £18.93 million
• Optionable: Not Optionable
• Beta: -0.26